Rein Therapeutics Reports 2026 Annual Meeting; Authorized Shares Increased

What Happened

• Rein Therapeutics, Inc. (RNTX) filed an 8-K on July 21, 2026 reporting results from its 2026 Annual Meeting of Stockholders. Stockholders elected two Class III directors — Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D. — and approved an amendment to increase authorized common stock from 100 million to 200 million shares. Stockholders also ratified CBIZ CPAs P.C. as the company’s independent registered public accounting firm for 2026 and approved, on an advisory (non‑binding) basis, the company’s executive compensation disclosure (say‑on‑pay).

Key Details

• Director elections:
  • Josef H. von Rickenbach: For 25,402,442; Withheld 13,202,963; Broker non‑votes 25,098,629.
  • Reinhard J. Ambros, Ph.D.: For 25,404,238; Withheld 13,201,167; Broker non‑votes 25,098,629.
• Authorized shares amendment (approved): For 61,004,221; Against 2,394,208; Abstain 305,605. No broker non‑votes on this item.
• Auditor ratification: CBIZ CPAs P.C. ratified — For 62,953,351; Against 172,420; Abstain 578,263. No broker non‑votes.
• Advisory vote on executive compensation (say‑on‑pay): For 37,628,483; Against 914,331; Abstain 62,591. There were 25,098,629 broker non‑votes on this advisory item.

Why It Matters

• The increase in authorized common shares (100M → 200M) gives the company the legal capacity to issue more shares in the future, which is a material corporate action that can affect share count and potential dilution for existing investors.
• Election of two directors confirms the current board composition for the Class III seats through the 2029 annual meeting.
• Ratification of CBIZ CPAs P.C. establishes the company’s independent auditor for 2026.
• The say‑on‑pay vote passed (advisory only), indicating majority shareholder support for the disclosed executive compensation even though broker non‑votes were present on that item.